Engineered antibodies

THE JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

(1911) · Journal of the American Medical Association · doi:10.1001/jama.1911.04260070032017 · Cited by 3,361

Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets

Clynes, R. A., Towers, T. L., Presta, L. G., & Ravetch, J. V. (2000) · Nature Medicine · doi:10.1038/74704 · Cited by 2,768

Crystal Structure of a Neutralizing Human IgG Against HIV-1: A Template for Vaccine Design

Saphire, E. O., Parren, P. W. H. I., Pantophlet, R., Zwick, M. B., Morris, G. M., Rudd, P. M., Dwek, R. A., Stanfield, R. L., Burton, D. R., & Wilson, I. A. (2001) · Science · doi:10.1126/science.1061692 · Cited by 942

Improving the efficacy of antibody-based cancer therapies

Carter, P. (2001) · Nature Reviews Cancer · doi:10.1038/35101072 · Cited by 833

Directed evolution of antibody fragments with monovalent femtomolar antigen-binding affinity

Boder, E. T., Midelfort, K. S., & Wittrup, K. D. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.170297297 · Cited by 673

Autoantigen microarrays for multiplex characterization of autoantibody responses

Robinson, W. H., DiGennaro, C., Hueber, W., Haab, B. B., Kamachi, M., Dean, E. J., Fournel, S., Fong, D., Genovese, M. C., De Vegvar, H. E. N., et al. (2002) · Nature Medicine · doi:10.1038/nm0302-295 · Cited by 673

Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery.

Park, J. W., Hong, K., Kirpotin, D. B., Colbern, G. T., Shalaby, R., Baselga, J. M., Shao, Y. Y., Nielsen, U. B., Marks, J. D., Moore, D. H., et al. (2002) · PubMed · Cited by 652

High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules.

Adams, G. P., Schier, R., McCall, A. M., Simmons, H. H., Horak, E. M., Alpaugh, R. K., Marks, J. D., & Weiner, L. M. (2001) · PubMed · Cited by 629

Herceptin acts as an anti-angiogenic cocktail

Izumi, Y., Xu, L., di Tomaso, E., Fukumura, D., & Jain, R. K. (2002) · Nature · doi:10.1038/416279b · Cited by 623

Antibodies inhibit prion propagation and clear cell cultures of prion infectivity

Peretz, D., Williamson, R. A., Kaneko, K., Vergara, J., Leclerc, E., Schmitt-Ulms, G., Mehlhorn, I. R., Legname, G., Wormald, M. R., Rudd, P. M., et al. (2001) · Nature · doi:10.1038/35089090 · Cited by 525

Differences in promiscuity for antibody–FcRn interactions across species: implications for therapeutic antibodies

Ober, R. J., Radu, C. G., Ghetie, V., & Ward, E. S. (2001) · International Immunology · doi:10.1093/intimm/13.12.1551 · Cited by 501

The use of mRNA display to select high-affinity protein-binding peptides

Wilson, D. S., Keefe, A. D., & Szostak, J. W. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.061028198 · Cited by 416

Picomolar affinity antibodies from a fully synthetic naive library selected and evolved by ribosome display

Hanes, J., Schaffitzel, C., Knappik, A., & Plückthun, A. (2000) · Nature Biotechnology · doi:10.1038/82407 · Cited by 373

Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody

Nowakowski, A., Wang, C., Powers, D. B., Amersdorfer, P., Smith, T. J., Montgomery, V. A., Sheridan, R., Blake, R., Smith, L. A., & Marks, J. D. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.172229899 · Cited by 331

Protection against anthrax toxin by recombinant antibody fragments correlates with antigen affinity

Maynard, J. A., Maassen, C. B. M., Leppla, S. H., Brasky, K., Patterson, J. L., Iverson, B. L., & Georgiou, G. (2002) · Nature Biotechnology · doi:10.1038/nbt0602-597 · Cited by 287

Design and application of diabodies, triabodies and tetrabodies for cancer targeting

Todorovska, A., Roovers, R. C., Dolezal, O., Kortt, A. A., Hoogenboom, H. R., & Hudson, P. J. (2001) · Journal of Immunological Methods · doi:10.1016/s0022-1759(00)00342-2 · Cited by 272

The antiviral activity of antibodies in vitro and in vivo

Parren, P. W. H. I., & Burton, D. R. (2001) · Advances in Immunology · doi:10.1016/s0065-2776(01)77018-6 · Cited by 261

Directed Evolution of High-Affinity Antibody Mimics Using mRNA Display

Xu, L., Aha, P., Gu, K., Kuimelis, R. G., Kurz, M., Lam, T., Lim, A. C., Liu, H., Lohse, P. A., Sun, L., et al. (2002) · Chemistry & Biology · doi:10.1016/s1074-5521(02)00187-4 · Cited by 251

Natural and designer binding sites made by phage display technology

Hoogenboom, H. R., & Chames, P. (2000) · Immunology Today · doi:10.1016/s0167-5699(00)01667-4 · Cited by 213

Human single-chain Fv intrabodies counteract in situ huntingtin aggregation in cellular models of Huntington's disease

Lecerf, J.-M., Shirley, T. L., Zhu, Q., Kazantsev, A., Amersdorfer, P., Housman, D. E., Messer, A., & Huston, J. S. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.071058398 · Cited by 199

Selection of tumor-specific internalizing human antibodies from phage libraries

Poul, M.-A., Becerril, B., Nielsen, U. B., Morisson, P., & Marks, J. D. (2000) · Journal of Molecular Biology · doi:10.1006/jmbi.2000.4026 · Cited by 192

Binding to CD20 by Anti-B1 Antibody or F(ab') 2 is sufficient for induction of apoptosis in B-cell lines

M. Cardarelli, M. Q. (2002) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-001-0247-1 · Cited by 189

Biophysical Properties of Camelid VHH Domains Compared to Those of Human VH3 Domains

Ewert, S., Cambillau, C., Conrath, K., & Plückthun, A. (2002) · Biochemistry · doi:10.1021/bi011239a · Cited by 184

Antigen Specificity and High Affinity Binding Provided by One Single Loop of a Camel Single-domain Antibody

Desmyter, A., Decanniere, K., Muyldermans, S., & Wyns, L. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m102107200 · Cited by 168

Bispecific human IgG by design

Carter, P. (2001) · Journal of Immunological Methods · doi:10.1016/s0022-1759(00)00339-2 · Cited by 167

Isolation of the new antigen receptor from wobbegong sharks, and use as a scaffold for the display of protein loop libraries

Nuttall, S. D., Krishnan, U. V., Hattarki, M. K., Gori, R. D., Irving, R. A., & Hudson, P. J. (2001) · Molecular Immunology · doi:10.1016/s0161-5890(01)00057-8 · Cited by 159

Functional expression of chimeric receptor genes in human T cells

Eshhar, Z., Waks, T., Bendavid, A., & Schindler, D. G. (2001) · Journal of Immunological Methods · doi:10.1016/s0022-1759(00)00343-4 · Cited by 158

Receptor-Mediated Gene Targeting to Tissues In Vivo Following Intravenous Administration of Pegylated Immunoliposomes

Shi, N., Boado, R. J., & Pardridge, W. M. (2001) · Pharmaceutical Research · doi:10.1023/a:1010910523202 · Cited by 156

High-throughput generation and engineering of recombinant human antibodies

Krebs, B., Rauchenberger, R., Reiffert, S. U., Rothe, C., Tesar, M., Thomassen, E., Cao, M., Dreier, T., Fischer, D., Höss, A., et al. (2001) · Journal of Immunological Methods · doi:10.1016/s0022-1759(01)00398-2 · Cited by 153

Stepwise in vitro affinity maturation of Vitaxin, an α v β 3 -specific humanized mAb

Wu, H., Beuerlein, G., Nie, Y., Smith, H., Lee, B. A., Hensler, M. E., Huse, W. D., & Watkins, J. D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6037 · Cited by 143

Fully human, HLA-DR-specific monoclonal antibodies efficiently induce programmed death of malignant lymphoid cells

Nagy, Z. A., Hubner, B., Löhning, C., Rauchenberger, R., Reiffert, S. U., Thomassen-Wolf, E., Zahn, S., Leyer, S., Schier, E. M., Zahradnik, A., et al. (2002) · Nature Medicine · doi:10.1038/nm736 · Cited by 141

Phage versus Phagemid Libraries for Generation of Human Monoclonal Antibodies

O’Connell, D. J., Becerril, B., Roy‐Burman, A., et al. (2002) · Journal of Molecular Biology · doi:10.1016/s0022-2836(02)00561-2 · Cited by 141

Correlation between in Vitro Stability and in Vivo Performance of Anti-GCN4 Intrabodies as Cytoplasmic Inhibitors

Wörn, A., der Maur, A. A., Escher, D., Honegger, A., Barberis, A., & Plückthun, A. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.4.2795 · Cited by 140

The intracellular antibody capture technology (IACT): towards a consensus sequence for intracellular antibodies

Visintin, M., Settanni, G., Maritan, A., Graziosi, S., Marks, J. D., & Cattaneo, A. (2002) · Journal of Molecular Biology · doi:10.1006/jmbi.2002.5392 · Cited by 135

Magic bullets hit the target

Gura, T. (2002) · Nature · doi:10.1038/417584a · Cited by 131

Tumor Targeting of Radiometal Labeled Anti-CEA Recombinant T84.66 Diabody and T84.66 Minibody: Comparison to Radioiodinated Fragments

Yazaki, P. J., Wu, A. M., Tsai, S.-W., Williams, L. E., Iklé, D. N., Wong, J. Y. C., Shively, J. E., & Raubitschek, A. A. (2001) · Bioconjugate Chemistry · doi:10.1021/bc000092h · Cited by 116

Advances in directed protein evolution by recursive genetic recombination: applications to therapeutic proteins

Kurtzman, A. L., Govindarajan, S., Vahle, K., Jones, J. T., Heinrichs, V., & Patten, P. A. (2001) · Current Opinion in Biotechnology · doi:10.1016/s0958-1669(00)00228-7 · Cited by 110

Towards proteome-wide production of monoclonal antibody by phage display

Liu, B., Huang, L., Sihlbom, C., et al. (2002) · Journal of Molecular Biology · doi:10.1006/jmbi.2001.5276 · Cited by 110

Ribosome display and affinity maturation: from antibodies to single V-domains and steps towards cancer therapeutics

Irving, R. A., Coia, G., Roberts, A., Nuttall, S. D., & Hudson, P. J. (2001) · Journal of Immunological Methods · doi:10.1016/s0022-1759(00)00341-0 · Cited by 96

Synergistic Antitumor Effect of Bispecific CD19 × CD3 and CD19 × CD16 Diabodies in a Preclinical Model of Non-Hodgkin’s Lymphoma

Kipriyanov, S. M., Cochlovius, B., Schäfer, H., Moldenhauer, G., Bähre, A., Gall, F. L., Knackmuss, S. H. J., & Little, M. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.1.137 · Cited by 91

Intracellular antibody capture technology: application to selection of intracellular antibodies recognising the BCR-ABL oncogenic protein

Tse, E., Lobato, M. N., Forster, A. M., Tanaka, T. U., Chung, G. T. Y., & Rabbitts, T. H. (2002) · Journal of Molecular Biology · doi:10.1006/jmbi.2002.5403 · Cited by 89

Radiation dosimetry results for zevalin radioimmunotherapy of rituximab-refractory non-hodgkin lymphoma

Wiseman, G. A., Leigh, B. R., Erwin, W. D., Lamonica, D. M., Kornmehl, E., SPIES, S. M., Silverman, D. H. S., Witzig, T. E., Sparks, R. B., & White, C. A. (2002) · Cancer · doi:10.1002/cncr.10305 · Cited by 84

Efficient and Selective Gene Transfer into Primary Human Brain Tumors by Using Single-Chain Antibody-Targeted Adenoviral Vectors with Native Tropism Abolished

van Beusechem, V. W., Grill, J., Mastenbroek, D. C. J., Wickham, T. J., Roelvink, P. W., Haisma, H. J., Lamfers, M. L. M., Dirven, C. M. F., Pinedo, H. M., & Gerritsen, W. R. (2002) · Journal of Virology · doi:10.1128/jvi.76.6.2753-2762.2002 · Cited by 83

Cytotoxic targeting of F9 teratocarcinoma tumours with anti-ED-B fibronectin scFv antibody modified liposomes

Marty, C., Odermatt, B., Schott, H. N., et al. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600423 · Cited by 79

A phage display selected Fab fragment with MHC class I-restricted specificity for MAGE-A1 allows for retargeting of primary human T lymphocytes

Willemsen, R., Debets, R., Hart, E., Hoogenboom, H. R., Bolhuis, R., & Chames, P. (2001) · Gene Therapy · doi:10.1038/sj.gt.3301570 · Cited by 76

Functional Neutralization of HIV-1 Vif Protein by Intracellular Immunization Inhibits Reverse Transcription and Viral Replication

Gonçalves, J., Aires‐da‐Silva, F., Freitas‐Vieira, A., Santa‐Marta, M., Malhó, R., Yang, X., Gabuzda, D. H., & Barbas, C. F. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m201906200 · Cited by 75

Expression of error-prone polymerases in BL2 cells activated for Ig somatic hypermutation

Poltoratsky, V. P., Woo, C. J., Tippin, B. L., Martín, A., Goodman, M. F., & Scharff, M. D. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.141222198 · Cited by 69

Building novel binding ligands to B7.1 and B7.2 based on human antibody single variable light chain domains 1 1Edited by I. A. Wilson

van den Beucken, T., van Neer, N., Sablon, E., Desmet, J., Celis, L., Hoogenboom, H. R., & Hufton, S. E. (2001) · Journal of Molecular Biology · doi:10.1006/jmbi.2001.4703 · Cited by 55

Efficient Isolation of Novel Human Monoclonal Antibodies with Neutralizing Activity Against HIV-1 from Transgenic Mice Expressing Human Ig Loci

He, Y., Honnen, W. J., Krachmarov, C. P., Burkhart, M. D., Kayman, S. C., Corvalán, J. R. F., & Pinter, A. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.1.595 · Cited by 55

Improved production and function of llama heavy chain antibody fragments by molecular evolution

van der Linden, R. H. J., de Geus, B., Frenken, L. G. J., Peters, H., & Verrips, C. T. (2000) · Journal of Biotechnology · doi:10.1016/s0168-1656(00)00274-1 · Cited by 51

Single-chain antibody-based gene therapy: inhibition of tumor growth by in situ production of phage-derived human antibody fragments blocking functionally active sites of cell-associated matrices

Sanz, L., Kristensen, P. K., Blanco, B., Facteau, S., Russell, S. J., Winter, G. P., & Álvarez‐Vallina, L. (2002) · Gene Therapy · doi:10.1038/sj.gt.3301725 · Cited by 50

ADAPTING PHARMACOKINETIC PROPERTIES OF A HUMANIZED ANTI-INTERLEUKIN-8 ANTIBODY FOR THERAPEUTIC APPLICATIONS USING SITE-SPECIFIC PEGYLATION

Leong, S. R., DeForge, L. E., Presta, L. G., González, T., Fan, A., Reichert, M., Chuntharapai, A., Kim, K. J., Tumas, D. B., Lee, W. P., et al. (2001) · Cytokine · doi:10.1006/cyto.2001.0936 · Cited by 49

With the benefit of hindsight

Milstein, C. (2000) · Immunology Today · doi:10.1016/s0167-5699(00)01660-1 · Cited by 46

Tumour targeting of humanised cross-linked divalent-fab′ antibody fragments: a clinical phase I/II study

Casey, J. L., Napier, M. P., King, D. J., Pedley, R. B., Chaplin, L. C., Weir, N., Skelton, L., Green, A. J., Hope‐Stone, L., Yarranton, G. T., et al. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600198 · Cited by 43

Biodistribution properties of (111)indium-labeled C-functionalized trans-cyclohexyl diethylenetriaminepentaacetic acid humanized 3S193 diabody and F(ab')(2) constructs in a breast carcinoma xenograft model.

Tahtis, K., Lee, F.-T., Smyth, F. E., Power, B. E., Renner, C., Brechbiel, M. W., Old, L. J., Hudson, P. J., & Scott, A. M. (2001) · PubMed · Cited by 38

Respiratory syncytial virus: recent progress towards the discovery of effective prophylactic and therapeutic agents

Meanwell, N. A., & Krystal, M. (2000) · Drug Discovery Today · doi:10.1016/s1359-6446(00)01500-2 · Cited by 35

Introduction: bispecific antibodies

Segal, D. M., Weiner, G. J., & Weiner, L. M. (2001) · Journal of Immunological Methods · doi:10.1016/s0022-1759(00)00338-0 · Cited by 33

Isolation of receptor–ligand pairs by capture of long-lived multivalent interaction complexes

de Wildt, R. M. T., Tomlinson, I. M., Ong, J. L., & Holliger, P. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.132008499 · Cited by 29

Improved renal clearance and tumor targeting of 99m Tc-labeled anti-Tac monoclonal antibody Fab by chemical modifications

Kim, M.-K., Jeong, H.-J., Kao, C.-H. K., et al. (2002) · Nuclear Medicine and Biology · doi:10.1016/s0969-8051(01)00296-7 · Cited by 17

Chemistry in living systems

Prescher, J. A., & Bertozzi, C. R. (2005) · Nature Chemical Biology · doi:10.1038/nchembio0605-13 · Cited by 1,456

The structural basis of antibody–antigen recognition

Sela-Culang, I., Kunik, V., & Ofran, Y. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00302 · Cited by 530

Antibody-Based Sensors: Principles, Problems and Potential for Detection of Pathogens and Associated Toxins

Byrne, B., Stack, E., Gilmartin, N., & O’Kennedy, R. (2009) · Sensors · doi:10.3390/s90604407 · Cited by 422

Endocan or endothelial cell specific molecule-1 (ESM-1): A potential novel endothelial cell marker and a new target for cancer therapy

Sarrazin, S., Adam, E., Lyon, M., Depontieu, F., Motte, V., Landolfi, C., Lortat-Jacob, H., Bechard, D., Lassalle, P., & Delehedde, M. (2006) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2005.08.004 · Cited by 337

Development trends for therapeutic antibody fragments

Nelson, A. L., & Reichert, J. M. (2009) · Nature Biotechnology · doi:10.1038/nbt0409-331 · Cited by 305